Cooperative Agreement U01CA295902
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $525K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Texas, USA
Similar Awards
- This Cooperative Agreement award, funded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports research to develop a non-invasive blood test for multi-cancer detection and determination of tissue of origin preceding overt cancer diagnosis. The $692,491 award, effective May 1, 2025 through April 30, 2030, will allow the University of Chicago to explore cancer-specific early epigenetic marks in circulating cell-free DNA and develop a highly sensitive...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $399,998 to Darwin Biosciences, Inc. to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. The device will incorporate sample collection, nucleic acid biomarker detection via isothermal recombinase polymerase amplification, and a visual readout on lateral flow strips. This work builds on Darwin Biosciences' prior...
- This federal Project Grant award of $429,399 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will fund research to "RECALIBRATE THE LUNG CANCER POLICY MODEL (LCPM) TO ADDRESS LUNG CANCER RISK AND LUNG CANCER SCREENING PRACTICES IN REAL-WORLD POPULATIONS." The goal is to improve the LCPM's accuracy in estimating the health and economic impacts of low-dose computed tomography (LDCT) lung cancer screening by 1) adjusting the model to reflect...
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $690,637 to the Beckman Research Institute of the City of Hope to develop and validate a minimally invasive, highly sensitive, and cost-effective blood-based test for the early detection of pancreatic ductal adenocarcinoma (PDAC). The test will harness the potential of 5-methylcytosine (5MC) and 5-hydroxy methylcytosine (5HMC) DNA modifications on circulating...
- The U.S. National Cancer Institute (NCI) awarded a $158,290 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Kaiser Foundation Hospitals to conduct a study on "Estimating Overdiagnosis After Implementation of Lung Cancer Screening in Community-Based Healthcare Systems." This 2-year project, running from July 2024 to July 2026, aims to produce estimates of overdiagnosis among patients diagnosed with lung cancer who participated in lung cancer...
- This $306,999 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) is focused on developing an integrated machine learning framework to accurately identify lung cancer subtypes. The key products and services to be delivered include: Establishing a gene signature-transfer machine learning model that leverages large-scale bulk and single-cell transcriptomics data, both within and beyond NIH Common Fund...
- The National Cancer Institute (NCI), part of the Department of Health and Human Services, awarded a $881,647 Project Grant to Panome Bio Inc. under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394). The grant supports research to advance untargeted metabolomics approaches for biomarker discovery in colon cancer. Specifically, Panome Bio is developing novel software and analytical methods to enhance the value and impact of untargeted metabolomics by addressing...
- The federal Project Grant was awarded by the National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The $764,448 grant was awarded to Cereus Diagnostics Corp. on August 1, 2025 to develop Lung-FAST, a rapid and cost-effective PCR-based test that can detect clinically actionable genetic mutations in lung cancer samples with high accuracy, even from small biopsy samples. The key...
- This $658,743 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Kaiser Foundation Hospitals aims to develop and validate prediction models for trajectories of function, cognition, and quality of life among adults aged 65 and older with advanced non-small cell lung cancer during up to 6 months of chemotherapy and/or immunotherapy. The 5-year project builds on an ongoing observational cohort study of 130 older adults with advanced lung...
- The National Cancer Institute awarded a $244,228 Project Grant to the University of Texas MD Anderson Cancer Center to develop a proteomics-driven approach to accurately map patient tumor samples to preclinical models in lung cancer research under the Cancer Detection and Diagnosis Research federal grant program (CFDA 93.394). The goal is to expand proteomic profiling of lung cancer patient-derived xenograft (PDX) models using reverse-phase protein arrays (RPPAs) to build a comprehensive...